{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:46:01Z","timestamp":1793807161464,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Swedish Orphan Biovitrum AG","id":[{"id":"https:\/\/ror.org\/04asvbz37","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1136\/ard-2022-223739","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T13:21:04Z","timestamp":1680268864000},"page":"857-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["Efficacy and safety of emapalumab in macrophage activation syndrome"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct02069899","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03311854","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03311854","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02069899","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02069899","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03311854","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-8232","authenticated-orcid":false,"given":"Fabrizio","family":"De Benedetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5717-136X","authenticated-orcid":false,"given":"Alexei A","family":"Grom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6178-6893","authenticated-orcid":false,"given":"Paul A","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9834-9619","authenticated-orcid":false,"given":"Claudia","family":"Bracaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pardeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Eleftheriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-0557","authenticated-orcid":false,"given":"Charalampia","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-7051","authenticated-orcid":false,"given":"Grant S","family":"Schulert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4219","authenticated-orcid":false,"given":"Jordi","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Laveille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Asnaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ballabio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Jacqmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"de Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223739_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223739_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset still's disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res"},{"key":"10.1136\/ard-2022-223739_bib4","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib5","article-title":"The elephant in the room: diagnostic\/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease [In press]","author":"Nigrovic","year":"2022","journal-title":"Pediatr Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/blood.2021013549","article-title":"Expansion of cd4dimcd8+ T cells characterizes macrophage activation syndrome and other secondary HLH","volume":"140","author":"De Matteis","year":"2022","journal-title":"Blood"},{"key":"10.1136\/ard-2022-223739_bib7","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020009499","article-title":"T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis","volume":"137","author":"Chaturvedi","year":"2021","journal-title":"Blood"},{"key":"10.1136\/ard-2022-223739_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.rdc.2021.06.003","article-title":"Pathogenesis and treatment of refractory disease courses in systemic juvenile idiopathic arthritis: refractory arthritis, recurrent macrophage activation syndrome and chronic lung disease","volume":"47","author":"Erkens","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2022-223739_bib9","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome-hemophagocytic lymphohistiocytosis","volume":"48","author":"Horne","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12969-015-0055-3","article-title":"Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"13","author":"Boom","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1136\/ard-2022-223739_bib12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"Verweyen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223739_bib13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","article-title":"Targeting interferon-\u03b3 in hyperinflammation: opportunities and challenges","volume":"17","author":"De Benedetti","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","article-title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","volume":"131","author":"Girard-Guyonvarc'h","year":"2018","journal-title":"Blood"},{"key":"10.1136\/ard-2022-223739_bib15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2022-223739_bib16","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"10.1136\/ard-2022-223739_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"10.1136\/ard-2022-223739_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223739_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"key":"10.1136\/ard-2022-223739_bib20","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1016\/S2665-9913(21)00139-9","article-title":"Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study","volume":"3","author":"Rodriguez-Smith","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib21","doi-asserted-by":"crossref","first-page":"108252","DOI":"10.1016\/j.clim.2019.108252","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"208","author":"Takakura","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1136\/ard-2022-223739_bib22","doi-asserted-by":"crossref","first-page":"46652","DOI":"10.1038\/srep46652","article-title":"Elevated circulating levels of the interferon-\u03b3-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset still's disease","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2022-223739_bib23","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib24","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223739_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib27","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223739_bib28","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/bcp.15133","article-title":"Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: a pharmacometric model-based approach","volume":"88","author":"Jacqmin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard-2022-223739_bib29","doi-asserted-by":"crossref","first-page":"663329","DOI":"10.3389\/fimmu.2021.663329","article-title":"Monocytes from patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis are hyperresponsive to interferon gamma","volume":"12","author":"Pascarella","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223739_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/annrheumdis-2020-217470","article-title":"Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-\u03b3 hyper-responsiveness and risk for macrophage activation syndrome","volume":"80","author":"Schulert","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223739_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","article-title":"Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections","volume":"3","author":"Lounder","year":"2019","journal-title":"Blood Adv"},{"key":"10.1136\/ard-2022-223739_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1136\/ard-2022-223739_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3324\/haematol.2020.255620","article-title":"Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated Bacillus Calmette-Gu\u00e9rin infection","volume":"106","author":"Tucci","year":"2021","journal-title":"Haematologica"},{"key":"10.1136\/ard-2022-223739_bib34","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1084\/jem.20190147","article-title":"A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant Cdc42 function","volume":"216","author":"Lam","year":"2019","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2022-223739_bib35","doi-asserted-by":"crossref","first-page":"e29026","DOI":"10.1002\/pbc.29026","article-title":"Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective","volume":"68","author":"Triebwasser","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1136\/ard-2022-223739_bib36","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s10875-021-01073-9","article-title":"T cell-Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (HLH) occurs in non-Asians and is associated with a T cell activation state that is comparable to primary HLH","volume":"41","author":"Shamriz","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1136\/ard-2022-223739_bib37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/atm-20-3127","article-title":"Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset still's disease: case report and review of the literature","volume":"8","author":"Gabr","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1136\/ard-2022-223739_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/2050-6511-14-40","article-title":"Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes","volume":"14","author":"Urien","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1136\/ard-2022-223739_bib39","doi-asserted-by":"crossref","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223739_bib41","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223739_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2021.05.007","article-title":"Anti-interferon-\u03b3 autoantibody-associated immunodeficiency","volume":"72","author":"Shih","year":"2021","journal-title":"Curr Opin Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:35:32Z","timestamp":1739504132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0003496724083985"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223739","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.12.22283141","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of emapalumab in macrophage activation syndrome","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}